$RNLXY
Renalytix plc Stock $rnlxy

$rnlxy Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-Q Financial Statement

#000095017024015276 Filed on February 14, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2022 Q4
Revenue	$535.0K	$709.0K	$2.161M
YoY Change	-26.1%	-67.19%	62.85%
Cost Of Revenue	$601.0K	$480.0K	$1.410M
YoY Change	-0.33%	-65.96%	74.5%
Gross Profit	-$66.00K	$229.0K	$751.0K
YoY Change	-154.55%	-69.51%	44.7%
Gross Profit Margin	-12.34%	32.3%	34.75%
Selling, General & Admin			$22.36M
YoY Change			-18.22%
% of Gross Profit			2977.36%
Research & Development	$2.216M	$3.225M	$3.326M
YoY Change	-43.8%	-3.04%
% of Gross Profit		1408.3%	442.88%
Depreciation & Amortization	$20.00K	$100.0K	$1.208M
YoY Change	-80.0%	-91.72%	-5.7%
% of Gross Profit		43.67%	160.85%
Operating Expenses	$6.487M	$8.870M	$22.36M
YoY Change	-41.23%	-60.33%	-18.59%
Operating Profit	-$6.553M	-$8.641M	-$21.61M
YoY Change	-39.97%	-60.01%	-19.81%
Interest Expense			-$1.193M
YoY Change			-801.76%
% of Operating Profit
Other Income/Expense, Net	-$49.00K	$161.0K	$154.0K
YoY Change	-115.81%	4.55%
Pretax Income	-$7.743M	-$8.481M	-$22.65M
YoY Change	-36.05%	-62.55%	-15.42%
Income Tax	$0.00	$4.000K	-$1.000K
% Of Pretax Income
Net Earnings	-$7.743M	-$8.485M	-$22.65M
YoY Change	-36.04%	-62.53%	-1.47%
Net Earnings / Revenue	-1447.29%	-1196.76%	-1047.99%
Basic Earnings Per Share	-$0.08	-$0.09	-$0.14
Diluted Earnings Per Share	-$0.08	-$0.09	-$0.30
COMMON SHARES
Basic Shares Outstanding	99.93M	97.43M	74.89M
Diluted Shares Outstanding	97.65M	97.27M	74.89M

Balance Sheet

Concept	2024 Q1	2023 Q4	2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments			$25.30M
YoY Change			-46.22%
Cash & Equivalents	$4.700M	$5.600M	$23.82M
Short-Term Investments			$1.487M
Other Short-Term Assets			$973.0K
YoY Change			-64.76%
Inventory			$917.0K
Prepaid Expenses
Receivables	$554.0K	$1.370M	$820.0K
Other Receivables			$0.00
Total Short-Term Assets	$6.340M	$8.250M	$28.01M
YoY Change		-70.55%	-45.46%
LONG-TERM ASSETS
Property, Plant & Equipment	$230.0K	$576.0K	$1.471M
YoY Change		-60.84%	-20.57%
Goodwill
YoY Change
Intangibles	$913.0K	$965.0K
YoY Change
Long-Term Investments			$0.00
YoY Change			-100.0%
Other Assets			$64.00K
YoY Change			-99.41%
Total Long-Term Assets	$2.429M	$3.026M	$14.60M
YoY Change		-79.28%	-50.51%
TOTAL ASSETS
Total Short-Term Assets	$6.340M	$8.250M	$28.01M
Total Long-Term Assets	$2.429M	$3.026M	$14.60M
Total Assets	$8.769M	$11.28M	$42.61M
YoY Change		-73.54%	-47.3%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable			$9.547M
YoY Change			11.66%
Accrued Expenses	$4.273M	$4.259M
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt			$0.00
YoY Change
Long-Term Debt Due			$4.756M
YoY Change			-1.39%
Total Short-Term Liabilities	$14.99M	$13.92M	$14.30M
YoY Change		-2.66%	59.52%
LONG-TERM LIABILITIES
Long-Term Debt			$7.506M
YoY Change			2902.4%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities			$7.506M
YoY Change			2902.4%
TOTAL LIABILITIES
Total Short-Term Liabilities	$14.99M	$13.92M	$14.30M
Total Long-Term Liabilities			$7.506M
Total Liabilities	$19.88M	$19.23M	$21.81M
YoY Change		-11.82%	136.64%
SHAREHOLDERS EQUITY
Retained Earnings	-$204.7M	-$197.0M
YoY Change
Common Stock	$195.2M	$190.7M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$11.11M	-$7.956M	$20.81M
YoY Change
Total Liabilities & Shareholders Equity	$8.769M	$11.28M	$42.61M
YoY Change		-73.54%	-47.3%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2022 Q4
OPERATING ACTIVITIES
Net Income	-$7.743M	-$8.485M	-$22.65M
YoY Change	-36.04%	-62.53%	-1.47%
Depreciation, Depletion And Amortization	$20.00K	$100.0K	$1.208M
YoY Change	-80.0%	-91.72%	-5.7%
Cash From Operating Activities			-$14.69M
YoY Change			-39.86%
INVESTING ACTIVITIES
Capital Expenditures			$0.00
YoY Change			-100.0%
Acquisitions
YoY Change
Other Investing Activities			-$64.00K
YoY Change
Cash From Investing Activities			-$64.00K
YoY Change			-90.02%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$116.0K
YoY Change			-41.12%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities			-1.614M
YoY Change			-711.36%
NET CHANGE
Cash From Operating Activities			-14.69M
Cash From Investing Activities			-64.00K
Cash From Financing Activities			-1.614M
Net Change In Cash			-16.37M
YoY Change			-34.01%
FREE CASH FLOW
Cash From Operating Activities			-$14.69M
Capital Expenditures			$0.00
Free Cash Flow			-$14.69M
YoY Change			-38.24%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
	dei	Amendment Flag AmendmentFlag	false
	dei	Entity Central Index Key EntityCentralIndexKey	0001811115
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	00-0000000
	dei	No Trading Symbol Flag NoTradingSymbolFlag	true
CY2023Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2023Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#LiabilitiesCurrent
CY2023Q2	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#LiabilitiesCurrent
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OperatingLeaseLiabilityNoncurrent
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OperatingLeaseLiabilityNoncurrent
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-39387
	dei	Entity Registrant Name EntityRegistrantName	Renalytix plc
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	X0
	dei	Entity Address Address Line1 EntityAddressAddressLine1	Finsgate5-7 Cranwood Street
	dei	Entity Address City Or Town EntityAddressCityOrTown	London
	dei	Entity Address Country EntityAddressCountry	GB
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	EC1V 9EE
	dei	City Area Code CityAreaCode	20
	dei	Local Phone Number LocalPhoneNumber	3139 2910
	dei	Security12b Title Security12bTitle	Ordinary shares, nominal value £0.0025 per share
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	false
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	99930156
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5619000
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	24682000
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1370000
CY2023Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	776000
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1261000
CY2023Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1424000
CY2023Q4	us-gaap	Assets Current AssetsCurrent	8250000
CY2023Q2	us-gaap	Assets Current AssetsCurrent	26882000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	576000
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1027000
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	102000
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	159000
CY2023Q4	us-gaap	Investment Owned At Fair Value InvestmentOwnedAtFairValue	1220000
CY2023Q2	us-gaap	Investment Owned At Fair Value InvestmentOwnedAtFairValue	1460000
CY2023Q4	us-gaap	Other Assets OtherAssets	1128000
CY2023Q2	us-gaap	Other Assets OtherAssets	1101000
CY2023Q4	us-gaap	Assets Assets	11276000
CY2023Q2	us-gaap	Assets Assets	30629000
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4259000
CY2023Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6644000
CY2023Q4	rnlx	Accrued Expenses Related Party Current AccruedExpensesRelatedPartyCurrent	3673000
CY2023Q2	rnlx	Accrued Expenses Related Party Current AccruedExpensesRelatedPartyCurrent	1963000
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	111000
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	130000
CY2023Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	3063000
CY2023Q2	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	4463000
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	13922000
CY2023Q2	us-gaap	Liabilities Current LiabilitiesCurrent	16136000
CY2023Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	5310000
CY2023Q2	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	7485000
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	0
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	41000
CY2023Q4	us-gaap	Liabilities Liabilities	19232000
CY2023Q2	us-gaap	Liabilities Liabilities	23662000
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0025
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0025
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	107189897
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	107189897
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	99930156
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	99930156
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	93781478
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	93781478
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	305000
CY2023Q2	us-gaap	Common Stock Value CommonStockValue	286000
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	190437000
CY2023Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	186456000
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1734000
CY2023Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1450000
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-196964000
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-178325000
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-7956000
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	6967000
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	11276000
CY2023Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	30629000
CY2023Q4	us-gaap	Revenues Revenues	709000
CY2022Q4	us-gaap	Revenues Revenues	1192000
	us-gaap	Revenues Revenues	1168000
	us-gaap	Revenues Revenues	2161000
CY2023Q4	us-gaap	Cost Of Revenue CostOfRevenue	480000
CY2022Q4	us-gaap	Cost Of Revenue CostOfRevenue	711000
	us-gaap	Cost Of Revenue CostOfRevenue	982000
	us-gaap	Cost Of Revenue CostOfRevenue	1407000
CY2023Q4	us-gaap	Gross Profit GrossProfit	229000
CY2022Q4	us-gaap	Gross Profit GrossProfit	481000
	us-gaap	Gross Profit GrossProfit	186000
	us-gaap	Gross Profit GrossProfit	754000
CY2023Q4	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	3225000
CY2022Q4	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	3326000
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	6012000
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	7083000
CY2023Q4	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5339000
CY2022Q4	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6810000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	11398000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	15060000
CY2023Q4	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	306000
CY2022Q4	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	306000
	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
CY2023Q4	rnlx	Performance Of Contract Liability To Affiliate PerformanceOfContractLiabilityToAffiliate	0
CY2022Q4	rnlx	Performance Of Contract Liability To Affiliate PerformanceOfContractLiabilityToAffiliate	7000
	rnlx	Performance Of Contract Liability To Affiliate PerformanceOfContractLiabilityToAffiliate	0
	rnlx	Performance Of Contract Liability To Affiliate PerformanceOfContractLiabilityToAffiliate	19000
CY2023Q4	us-gaap	Operating Expenses OperatingExpenses	8870000
CY2022Q4	us-gaap	Operating Expenses OperatingExpenses	10129000
	us-gaap	Operating Expenses OperatingExpenses	17716000
	us-gaap	Operating Expenses OperatingExpenses	22124000
CY2023Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-8641000
CY2022Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-9648000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-17530000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-21370000
CY2023Q4	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	0
CY2022Q4	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	0
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	0
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-9000
CY2023Q4	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-89000
CY2022Q4	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-108000
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	200000
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	699000
CY2023Q4	rnlx	Fair Value Adjustment To Vericidx Investment FairValueAdjustmentToVericidxInvestment	-202000
CY2022Q4	rnlx	Fair Value Adjustment To Vericidx Investment FairValueAdjustmentToVericidxInvestment	345000
	rnlx	Fair Value Adjustment To Vericidx Investment FairValueAdjustmentToVericidxInvestment	245000
	rnlx	Fair Value Adjustment To Vericidx Investment FairValueAdjustmentToVericidxInvestment	1199000
CY2023Q4	rnlx	Fair Value Adjustment To Convertible Notes FairValueAdjustmentToConvertibleNotes	114000
CY2022Q4	rnlx	Fair Value Adjustment To Convertible Notes FairValueAdjustmentToConvertibleNotes	440000
	rnlx	Fair Value Adjustment To Convertible Notes FairValueAdjustmentToConvertibleNotes	1321000
	rnlx	Fair Value Adjustment To Convertible Notes FairValueAdjustmentToConvertibleNotes	730000
CY2023Q4	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	161000
CY2022Q4	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	97000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	261000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	211000
CY2023Q4	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-8481000
CY2022Q4	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-10444000
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-18635000
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-22398000
CY2023Q4	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4000
CY2022Q4	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4000
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1000
CY2023Q4	us-gaap	Net Income Loss NetIncomeLoss	-8485000
CY2022Q4	us-gaap	Net Income Loss NetIncomeLoss	-10444000
	us-gaap	Net Income Loss NetIncomeLoss	-18639000
	us-gaap	Net Income Loss NetIncomeLoss	-22397000
CY2023Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.09
CY2022Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.14
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.19
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.3
CY2022Q4	rnlx	Changes In The Fair Value Of The Convertible Notes ChangesInTheFairValueOfTheConvertibleNotes	-920000
CY2023Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.09
CY2022Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.14
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.19
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.3
CY2023Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	97268051
CY2022Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	74891844
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	96017946
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	74848278
CY2023Q4	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	97268051
CY2022Q4	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	74891844
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	96017946
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	74848278
CY2023Q4	rnlx	Changes In Fair Value Of Convertible Notes ChangesInFairValueOfConvertibleNotes	0
CY2022Q4	rnlx	Changes In Fair Value Of Convertible Notes ChangesInFairValueOfConvertibleNotes	-920000
	rnlx	Changes In Fair Value Of Convertible Notes ChangesInFairValueOfConvertibleNotes	75000
	rnlx	Changes In Fair Value Of Convertible Notes ChangesInFairValueOfConvertibleNotes	-523000
CY2023Q4	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-401000
CY2022Q4	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	588000
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-359000
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-499000
CY2023Q4	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	8886000
CY2022Q4	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	10776000
	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	18923000
	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	23419000
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	6967000
CY2023Q3	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	1054000
CY2023Q3	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	1000
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	524000
CY2023Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	42000
CY2023Q3	rnlx	Changes In The Fair Value Of The Convertible Notes ChangesInTheFairValueOfTheConvertibleNotes	75000
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-10154000
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	-1491000
CY2023Q4	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	1943000
CY2023Q4	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	93000
CY2023Q4	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	385000
CY2023Q4	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-401000
CY2023Q4	us-gaap	Net Income Loss NetIncomeLoss	-8485000
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-7956000
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	30607000
CY2022Q3	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	116000
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	763000
CY2022Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-1087000
CY2022Q3	rnlx	Changes In The Fair Value Of The Convertible Notes ChangesInTheFairValueOfTheConvertibleNotes	397000
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-11953000
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	18843000
CY2022Q4	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	818000
CY2022Q4	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	588000
CY2022Q4	us-gaap	Net Income Loss NetIncomeLoss	-10444000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	8885000
	us-gaap	Net Income Loss NetIncomeLoss	-18639000
	us-gaap	Net Income Loss NetIncomeLoss	-22397000
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	235000
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	258000
	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	306000
	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
	us-gaap	Share Based Compensation ShareBasedCompensation	909000
	us-gaap	Share Based Compensation ShareBasedCompensation	1584000
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	0
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-9000
	rnlx	Reversal Of Kantaro Liability ReversalOfKantaroLiability	0
	rnlx	Reversal Of Kantaro Liability ReversalOfKantaroLiability	55000
	rnlx	Fair Value Adjustment To Vericidx Investment FairValueAdjustmentToVericidxInvestment	245000
	rnlx	Fair Value Adjustment To Vericidx Investment FairValueAdjustmentToVericidxInvestment	1199000
	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-0
	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-271000
	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	163000
	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	0
	rnlx	Fair Value Adjustments To Convertible Debt FairValueAdjustmentsToConvertibleDebt	1059000
	rnlx	Fair Value Adjustments To Convertible Debt FairValueAdjustmentsToConvertibleDebt	730000
	rnlx	Non Cash Lease Expense NonCashLeaseExpense	57000
	rnlx	Non Cash Lease Expense NonCashLeaseExpense	52000
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	594000
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-81000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-45000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-494000
	us-gaap	Increase Decrease In Due From Affiliates Current IncreaseDecreaseInDueFromAffiliatesCurrent	0
	us-gaap	Increase Decrease In Due From Affiliates Current IncreaseDecreaseInDueFromAffiliatesCurrent	22000
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	618000
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	2773000
	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	-744000
	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	-1083000
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-2465000
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1367000
	rnlx	Increase Decrease In Accrued Expenses Related Party IncreaseDecreaseInAccruedExpensesRelatedParty	1708000
	rnlx	Increase Decrease In Accrued Expenses Related Party IncreaseDecreaseInAccruedExpensesRelatedParty	-566000
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	0
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-46000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-17423000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-15351000
	rnlx	Payment For Long Term Deferred Expense PaymentForLongTermDeferredExpense	0
	rnlx	Payment For Long Term Deferred Expense PaymentForLongTermDeferredExpense	64000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-64000
	rnlx	Payment Of Convertible Notes Principal PaymentOfConvertibleNotesPrincipal	1660000
	rnlx	Payment Of Convertible Notes Principal PaymentOfConvertibleNotesPrincipal	1648000
	rnlx	Payments Of Debt Issuance Costs1 PaymentsOfDebtIssuanceCosts1	5000
	rnlx	Payments Of Debt Issuance Costs1 PaymentsOfDebtIssuanceCosts1	0
	rnlx	Proceeds From The Issuance Of Ordinary Shares Under Employee Share Purchase Plan ProceedsFromTheIssuanceOfOrdinarySharesUnderEmployeeSharePurchasePlan	93000
	rnlx	Proceeds From The Issuance Of Ordinary Shares Under Employee Share Purchase Plan ProceedsFromTheIssuanceOfOrdinarySharesUnderEmployeeSharePurchasePlan	116000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1572000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1532000
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-68000
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-570000
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-19063000
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-17517000
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	24682000
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	41333000
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	5619000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	23816000
	us-gaap	Interest Paid Net InterestPaidNet	249000
	us-gaap	Interest Paid Net InterestPaidNet	0
	us-gaap	Nature Of Operations NatureOfOperations	<p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1. Business and risks</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Renalytix PLC and its wholly-owned subsidiaries, the “Company” or "Renalytix" is an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and significantly lower healthcare costs. KidneyIntelX, the Company’s first-in-class diagnostic platform, employs a proprietary artificial intelligence-enabled algorithm that combines diverse data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from EHR systems, to generate a unique patient risk score. Additionally, the Company has successfully completed a statement of work with AstraZeneca Pharmaceuticals LP (“AstraZeneca”) to conduct a feasibility study to determine the impact of the use of the Company’s KidneyIntelX platform to optimize utilization of various CKD agents. As a result of the initial success with AstraZeneca the Company plans to pursue further collaborations with pharmaceutical companies and make ‘Pharmaceutical Services Revenue’ a core part of the business going forward with the goal of improving guideline-based standard-of-care for optimal utilization of existing and novel therapeutics using the KidneyIntelX testing platform and proprietary care management software.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Since inception in March 2018, the Company has focused primarily on organizing and staffing the Company, raising capital, developing the KidneyIntelX platform, conducting clinical validation studies for KidneyIntelX, establishing and protecting its intellectual property portfolio and commercial laboratory operations, pursuing regulatory clearance and developing a reimbursement strategy. The Company has funded its operations primarily through equity and debt financings.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is subject to risks and uncertainties common to early-stage companies in the diagnostics industry, including, but not limited to, ability to secure additional capital to fund operations, compliance with governmental regulations, development by competitors of new technological innovations, dependence on key personnel and protection of proprietary technology. To achieve widespread usage, KidneyIntelX and additional diagnostic products currently under development will require extensive clinical testing and validation prior to regulatory approval and commercialization. These efforts require significant amounts of additional capital, adequate personnel, and infrastructure, and extensive compliance-reporting capabilities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-197000000
	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Due to the uncertainty of factors surrounding the estimates or judgments used in the preparation of the consolidated financial statements, actual results may materially vary from these estimates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Estimates and assumptions are periodically reviewed, and the effects of revisions are reflected in the consolidated financial statements in the period they are determined to be necessary. Significant areas that require management’s estimate include the assumptions used in determining the fair value of share-based awards, determining the fair value of the bonds, recording the prepaid/accrual and associated expense for research and development activities performed for the Company by third parties and determining useful lives of property and equipment and capitalized software.</span></p>
CY2023Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	100000
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5600000
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	24700000
CY2023Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	100000
CY2023Q2	us-gaap	Accounts Receivable Net AccountsReceivableNet	100000
CY2023Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	11948000
	rnlx	Change Due To Payment Of Principal And Interest ChangeDueToPaymentOfPrincipalAndInterest	-4911000
	rnlx	Fair Value Adjustments FairValueAdjustments	1321000
	rnlx	Change In Credit Risk Associated With Fair Value ChangeInCreditRiskAssociatedWithFairValue	-75000
	rnlx	Fair Value Fx Impact FairValueFxImpact	90000
CY2023Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	8373000
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	998000
CY2023Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1877000
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	422000
CY2023Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	850000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	576000
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1027000
CY2023Q4	us-gaap	Depreciation Depreciation	100000
	us-gaap	Depreciation Depreciation	200000
CY2022Q4	us-gaap	Depreciation Depreciation	100000
	us-gaap	Depreciation Depreciation	200000
CY2023Q4	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	1535000
CY2023Q2	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	1526000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	570000
CY2023Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	476000
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	965000
CY2023Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1050000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	92000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	184000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	141000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	126000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	126000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	296000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	965000
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	909000
CY2023Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	442000
CY2023Q4	rnlx	Accrued Research And Development Expenses Current AccruedResearchAndDevelopmentExpensesCurrent	1180000
CY2023Q2	rnlx	Accrued Research And Development Expenses Current AccruedResearchAndDevelopmentExpensesCurrent	1657000
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1212000
CY2023Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3866000
CY2023Q4	rnlx	Accrued License And Royalty Expense AccruedLicenseAndRoyaltyExpense	737000
CY2023Q2	rnlx	Accrued License And Royalty Expense AccruedLicenseAndRoyaltyExpense	669000
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	221000
CY2023Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	10000
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4259000
CY2023Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6644000
CY2022Q2	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	21200000
CY2022Q2	rnlx	Senior Convertible Bond Par Value Percentage SeniorConvertibleBondParValuePercentage	0.85
CY2022Q2	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	18000000
CY2022Q2	us-gaap	Debt Instrument Interest Rate Effective Percentage DebtInstrumentInterestRateEffectivePercentage	0.055
CY2022Q2	rnlx	Debt Instrument Convertible Conversion Price Percentage DebtInstrumentConvertibleConversionPricePercentage	0.20
CY2022Q2	rnlx	Debt Instrument Reset Down Term1 DebtInstrumentResetDownTerm1	P12M
CY2022Q2	rnlx	Debt Instrument Reset Down Term2 DebtInstrumentResetDownTerm2	P24M
CY2022Q2	rnlx	Debt Instrument Reset Down Term3 DebtInstrumentResetDownTerm3	P36M
CY2022Q2	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	7.25
CY2023Q1	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	8.2508
CY2023Q1	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	6.8757
CY2022Q2	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	7.25
CY2023Q1	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	8.2508
CY2023Q2	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	7.7924
CY2022Q2	rnlx	Repayment Of Deferred Amortization Percentage RepaymentOfDeferredAmortizationPercentage	1
CY2023Q3	rnlx	Amount Of Cash Amortization Payment AmountOfCashAmortizationPayment	1400000
CY2023Q3	rnlx	Principal Of Amount Of Cash Amortization PrincipalOfAmountOfCashAmortization	1100000
CY2023Q3	rnlx	Amount Of Cash Amortization Interest Payment AmountOfCashAmortizationInterestPayment	300000
CY2023Q3	rnlx	Acceleratedamountofcashamortizationrepayment Acceleratedamountofcashamortizationrepayment	1060000.00
CY2023Q4	rnlx	Amount Of Cash Amortization Payment AmountOfCashAmortizationPayment	1300000
CY2023Q4	rnlx	Principal Of Amount Of Cash Amortization PrincipalOfAmountOfCashAmortization	1100000
CY2023Q4	rnlx	Amount Of Cash Amortization Interest Payment AmountOfCashAmortizationInterestPayment	200000
CY2023Q4	rnlx	Amount Of Cash Amortization Payment AmountOfCashAmortizationPayment	1300000
CY2023Q4	rnlx	Principal Of Amount Of Cash Amortization PrincipalOfAmountOfCashAmortization	1100000
CY2023Q4	rnlx	Amount Of Cash Amortization Interest Payment AmountOfCashAmortizationInterestPayment	200000
CY2023Q4	rnlx	Amortization Payment In Cash AmortizationPaymentInCash	600000
	rnlx	Principal Amount Outstanding Of Cash Amortization PrincipalAmountOutstandingOfCashAmortization	13800000
CY2022Q2	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	16900000
CY2022Q2	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	1400000
CY2023Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	8500000
	rnlx	Incremental Borrowing Rate Of Average Commercial Real Estate Loans IncrementalBorrowingRateOfAverageCommercialRealEstateLoans	0.10
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	102000
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	159000
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	111000
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	130000
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	0
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	41000
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	111000
CY2023Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	171000
	us-gaap	Short Term Lease Cost ShortTermLeaseCost	173000
	us-gaap	Short Term Lease Cost ShortTermLeaseCost	183000
	us-gaap	Lease Cost LeaseCost	336000
	us-gaap	Lease Cost LeaseCost	343000
	us-gaap	Operating Lease Payments OperatingLeasePayments	64000
	us-gaap	Operating Lease Payments OperatingLeasePayments	64000
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P0Y10M24D
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y10M24D
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.10
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.10
CY2023Q4	us-gaap	Short Term Lease Cost ShortTermLeaseCost	92000
CY2022Q4	us-gaap	Short Term Lease Cost ShortTermLeaseCost	92000
CY2023Q4	us-gaap	Lease Cost LeaseCost	166000
CY2022Q4	us-gaap	Lease Cost LeaseCost	170000
CY2023Q4	us-gaap	Operating Lease Payments OperatingLeasePayments	32000
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	33000
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P0Y10M24D
CY2022Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y10M24D
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.10
CY2022Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.10
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	116000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	0
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	0
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	116000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	5000
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	111000
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	107189897
	us-gaap	Dividends Cash DividendsCash	0
CY2023Q4	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	385000
CY2022Q4	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	815000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	909000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1578000
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y4M24D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y1M6D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.743
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.669
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.043
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.032
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4968576
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.5
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y8M12D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2673296
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.32
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	380568
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	5.48
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	1563
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	6.68
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	7259741
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.29
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y3M18D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	4452018
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	4.29
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	7259741
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	3.29
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P7Y3M18D
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11907050
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7228923

Files In Submission

Name	View Source	Status
0000950170-24-015276-index-headers.html	Edgar Link	pending
0000950170-24-015276-index.html	Edgar Link	pending
0000950170-24-015276.txt	Edgar Link	pending
0000950170-24-015276-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
img83610915_0.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
rnlx-20231231.htm	Edgar Link	pending
rnlx-20231231.xsd	Edgar Link	pending
rnlx-ex31_1.htm	Edgar Link	pending
rnlx-ex31_2.htm	Edgar Link	pending
rnlx-ex32_1.htm	Edgar Link	pending
rnlx-ex3_1.htm	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
rnlx-20231231_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$RNLXY
Renalytix plc Stock $rnlxy

2024 Q1 Form 10-Q Financial Statement

#000095017024015276 Filed on February 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RNLXY Renalytix plc Stock $rnlxy

2024 Q1 Form 10-Q Financial Statement

#000095017024015276 Filed on February 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RNLXY
Renalytix plc Stock $rnlxy